When an antidepressant fails to lift symptoms, many people conclude the medicine is at fault and that switching to another pill is the obvious move. Yet deciding treatment has stalled is a judgment formed across weeks and months, and it draws on more than a single disappointing experience. Understanding how that judgment is reached may ease some of the tension before the next visit.
Clinicians usually do not label a treatment as ineffective after a single slow week. Antidepressants often take several weeks to show their effect, and the early period can bring side effects before any benefit appears. So the first questions are whether the medication was given long enough, whether the dose was actually reached, and whether it was taken consistently. A brief trial at a low dose tells a clinician much less than a steady trial at an adequate dose.
What stalled usually means
Stalled does not mean nothing changed. Many people notice small shifts, such as sleeping a little better, getting out of bed earlier, or feeling less flat in the afternoon, while the core low mood stays put. Clinicians weigh these partial changes alongside the main symptoms. A treatment may be judged to have helped a little but not enough, or to have had no real effect at all. Those are different situations, and they tend to lead to different next steps.
Your own account matters a great deal here. Clinicians often rely on what you report about sleep, energy, concentration, appetite, and interest in everyday life, along with what a family member or partner has observed. Questionnaires may also be used, but they are one piece of the picture, not a replacement for what you describe in your own words.
Why the clinician checks other causes first
Before pinning the problem on the treatment itself, a thorough clinician often checks for conditions that can keep mood down no matter which drug is prescribed. Thyroid problems, sleep disorders, alcohol or other drug use, persistent pain, and certain other medications are typical examples. Once these are dealt with, the situation sometimes becomes easier to read. Doing this does not mean your worries are being dismissed. It means the team avoids switching a medication when the true barrier is somewhere else.
Consistency is part of this check too. Missed doses, stopping early because of side effects, or taking a medicine only on some days can make a treatment look like it failed when it never received a fair chance. Being open about this is useful, and it does not have to feel like a confession.
How the next step is usually chosen
Once a trial is judged to have fallen short, the clinician usually considers a few broad directions. One is to adjust the current medicine, for example by raising the dose if it was still on the low side. Another is to add a second agent alongside the first. A third is to switch to a different class of medicine. Psychotherapy may be added next to medication, and in some cases other treatments are discussed. The choice depends on what was already tried, how it was tolerated, your health history, and what you can realistically manage from week to week.
Clinicians also try to change one major variable at a time when they can. That makes it easier to tell later what helped and what did not. It is one reason a plan can feel slow. Each step is meant to produce information, not just a new name on a prescription list.
Keeping the decision workable for you
The best next step is one you can actually follow. A treatment that requires daily doses you tend to forget, frequent travel you cannot fit in, or costs you cannot sustain may fail in practice even if it looks strong on paper. Say so early. Clinicians can often adjust timing, choose a different format, or check coverage before a plan is set.
Settling in advance on what counts as an adequate trial, along with a schedule for follow-up, is worthwhile. Keeping a log of when each medicine was begun and stopped, and what shifted during that time, gives you and your prescriber a more precise common reference. A treatment that has plateaued does not mean depression is untreatable. It indicates the approach should be reconsidered, and that reconsideration typically points toward a more targeted option.